Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
For the past decades, an acidic pH has been used to render Mycobacterium tuberculosis susceptible to pyrazinamide for in vitro testing. Here, we show that at the standard breakpoint concentration and reduced culture temperatures, pyrazinamide (PZA) is active against tuberculosis (TB) at neutral pH. This finding should help unravel the mechanism of action of PZA and allow drug susceptibility testing (DST) methods to be optimized. P yrazinamide (PZA) is an important drug for TB treatment. PZA is used in standard first-and second-line therapies and is also included in many new regimens due to its unique ability to shorten therapy (1, 2).The mechanism of action of PZA is unresolved (3), but it is commonly assumed that a low pH is required for PZA activity against Mycobacterium tuberculosis. In a widely accepted model proposed by Zhang and Mitchison (4), low pH causes the protonation of extracellular pyrazinoic acid (POA; the enzymatically activated form of PZA) required for POA to reenter mycobacteria and exert its antimicrobial effect. In addition, the reduced membrane potential at low pH was proposed to facilitate energy depletion by PZA (5). However, the activity of PZA in vivo and in vitro is directed against nonmetabolizing, or slowly metabolizing, mycobacteria (1, 6), and the role of low pH on the transcriptional remodeling of M. tuberculosis known to occur under those conditions (7-9) might also be related to the antimicrobial effects of PZA at low pH. We believe the relative contribution of the protonation and metabolic effects deserves investigation and might help elucidate PZA's mechanism of action in vivo.Due to the incompletely resolved mechanism, developments in drug susceptibility testing (DST) have been limited to testing at reduced pH. Partly due to the suboptimal growth of the bacteria at low pH, the conditions are difficult to control, and PZA DST results in more failures and a lower test accuracy and reproducibility than those of other first-line drugs (10-12).It was previously demonstrated that under acidic conditions, PZA activity is enhanced by lowering the temperature (13), but the effect of low temperature alone was not assessed. To investigate how dependent the action of PZA is on low pH, we determined the susceptibility of TB to PZA at reduced temperature at neutral pH. MATERIALS AND METHODS Strains.The tested strains are presented in Table 1. M. tuberculosis strains 12-17995 and 12-17889 are clinical isolates from Georgia (14) from the Beijing lineage. Strain 12-17889 is closely related to the previously described clade A strains sharing a pncA I6L mutation (15). Apart from the pncA I6L mutation, no additional mutation in pncA is present in this strain.Microcolony-based growth rate determination. Measurement of the effect of antimicrobials on TB microcolonies on solid medium was performed essentially as previously described (16). In short, aliquots of liquid cultures, sieved through a 5-m-pore filter, were inoculated on 8 by 8-mm squares of porous supports on nonselective MB7H11 agar (BD, ...
For the past decades, an acidic pH has been used to render Mycobacterium tuberculosis susceptible to pyrazinamide for in vitro testing. Here, we show that at the standard breakpoint concentration and reduced culture temperatures, pyrazinamide (PZA) is active against tuberculosis (TB) at neutral pH. This finding should help unravel the mechanism of action of PZA and allow drug susceptibility testing (DST) methods to be optimized. P yrazinamide (PZA) is an important drug for TB treatment. PZA is used in standard first-and second-line therapies and is also included in many new regimens due to its unique ability to shorten therapy (1, 2).The mechanism of action of PZA is unresolved (3), but it is commonly assumed that a low pH is required for PZA activity against Mycobacterium tuberculosis. In a widely accepted model proposed by Zhang and Mitchison (4), low pH causes the protonation of extracellular pyrazinoic acid (POA; the enzymatically activated form of PZA) required for POA to reenter mycobacteria and exert its antimicrobial effect. In addition, the reduced membrane potential at low pH was proposed to facilitate energy depletion by PZA (5). However, the activity of PZA in vivo and in vitro is directed against nonmetabolizing, or slowly metabolizing, mycobacteria (1, 6), and the role of low pH on the transcriptional remodeling of M. tuberculosis known to occur under those conditions (7-9) might also be related to the antimicrobial effects of PZA at low pH. We believe the relative contribution of the protonation and metabolic effects deserves investigation and might help elucidate PZA's mechanism of action in vivo.Due to the incompletely resolved mechanism, developments in drug susceptibility testing (DST) have been limited to testing at reduced pH. Partly due to the suboptimal growth of the bacteria at low pH, the conditions are difficult to control, and PZA DST results in more failures and a lower test accuracy and reproducibility than those of other first-line drugs (10-12).It was previously demonstrated that under acidic conditions, PZA activity is enhanced by lowering the temperature (13), but the effect of low temperature alone was not assessed. To investigate how dependent the action of PZA is on low pH, we determined the susceptibility of TB to PZA at reduced temperature at neutral pH. MATERIALS AND METHODS Strains.The tested strains are presented in Table 1. M. tuberculosis strains 12-17995 and 12-17889 are clinical isolates from Georgia (14) from the Beijing lineage. Strain 12-17889 is closely related to the previously described clade A strains sharing a pncA I6L mutation (15). Apart from the pncA I6L mutation, no additional mutation in pncA is present in this strain.Microcolony-based growth rate determination. Measurement of the effect of antimicrobials on TB microcolonies on solid medium was performed essentially as previously described (16). In short, aliquots of liquid cultures, sieved through a 5-m-pore filter, were inoculated on 8 by 8-mm squares of porous supports on nonselective MB7H11 agar (BD, ...
BackgroundThe ongoing epidemic of multidrug-resistant tuberculosis (MDR-TB) in Georgia highlights the need for more effective control strategies. A new regimen to treat MDR-TB that includes pyrazinamide (PZA) is currently being evaluated and PZA resistance status will largely influence the success of current and future treatment strategies. PZA susceptibility testing was not routinely performed at the National Reference Laboratory (NRL) in Tbilisi between 2010 and September 2015. We here provide a first insight into the prevalence of PZA resistant TB in this region.MethodsPhenotypic susceptibility to PZA was determined in a convenience collection of well-characterised TB patient isolates collected at the NRL in Tbilisi between 2012 and 2013. In addition, the pncA gene was sequenced and whole genome sequencing was performed on two isolates.ResultsOut of 57 isolates tested 33 (57.9%) showed phenotypic drug resistance to PZA and had a single pncA mutation. All of these 33 isolates were MDR-TB strains. pncA mutations were absent in all but one of the 24 PZA susceptible isolate. In total we found 18 polymorphisms in the pncA gene. From the two major MDR-TB clusters represented (94–32 and 100–32), 10 of 15, 67.0% and 13 of 14, 93.0% strains, respectively were PZA resistant. We also identified a member of the potentially highly transmissive clade A strain carrying the characteristic I6L substitution in PncA. Another strain with the same MLVA type as the clade A strain acquired a different mutation in pncA and was genetically more distantly related suggesting that different branches of this particular lineage have been introduced into this region.ConclusionIn this high MDR-TB setting more than half of the tested MDR-TB isolates were resistant to PZA. As PZA is part of current and planned MDR-TB treatment regimens this is alarming and deserves the attention of health authorities. Based on our typing and sequence analysis results we conclude that PZA resistance is the result of primary transmission as well as acquisition within the patient and recommend prospective genotyping and PZA resistance testing in high MDR-TB settings. This is of utmost importance in order to preserve bacterial susceptibility to PZA to help protect (new) second line drugs in PZA containing regimens.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.